Navigation Links
New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
Date:5/14/2009

strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

(1) Trials include MADIT, MADIT II, CONTAK-CD, and COMPANION.

    CONTACT:  David Knutson
              651-582-6574 (office)
              651-260-8288 (cell)
              Media Relations
              Boston Scientific Corporation

              Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Fortune Oil ... officially changed its name to Manzo Pharmaceuticals, Inc. with ... to take effect today, September 17, 2014. Also taking ... The approval is a pivotal event in ... . Mr. Manzo explained, "We could not proceed with ...
(Date:9/17/2014)...  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... received an unsolicited, non-binding proposal from Endo International plc ... the outstanding shares of Auxilium common stock at a ... stock, subject to due diligence, financing and other conditions. ... received from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... 2014 Mindray (NYSE: MR)announced its new generation ... system has been showcased for the first time at ... September, and is scheduled for availability in the U.S. ... the most efficient workhorse in the mid-range segment, the ... perfectly optimized user experience including a gesture-sensitive touch screen, ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
(Date:9/17/2014)... Oxford, UK, September 17, 2014 The International Journal ... has opened up its archive of previously published content: after ... read. A key aim of the IJS is ... hoped that by making these articles available to all will ... Editor-in-Chief of IJS said, "The journal has always ...
(Date:9/17/2014)... WA (PRWEB) September 17, 2014 A ... in fiscal year 2010 revealed 3.2% of these patients developed ... and 2.4% labeled as superficial SSIs. The average difference for ... 876, after adjustments. , The study, conducted by Marin Schweizer, ... the University of Iowa, found the treatment costs for the ...
(Date:9/17/2014)... September 17, 2014 The probability of ... with regular screening and examination, a healthy diet could ... of Epicure with the Chef MDs, renowned ... Paul Rusilko to prepare a delicious Fish Moilee. , ... diets that influence risk of prostate cancer, uncommonly found ...
(Date:9/17/2014)... Acceleratio Ltd., an innovative software development ... of Server Monitoring Toolkit , a web ... It brings real-time server monitoring via a live ... enhanced features that significantly improve troubleshooting and detection ... agentless data collection, a user-friendly interface, and many ...
(Date:9/17/2014)... September 17, 2014 Kamut International is ... a key ingredient in Michael Angelo’s new “Made With ... new fully organic lasagna ready made, frozen meal. Michael ... pastas and these new products align well with Kamut ... all KAMUT® Brand wheat must be grown certified organic. ...
Breaking Medicine News(10 mins):Health News:Three Ways to Minimize Costs Associated with Surgical Site Infections 2Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 3Health News:KAMUT® Brand Wheat Delivers a High Quality Ingredient and Authentic Italian Taste for Michael Angelo’s New Ready-Made Meals featuring Organic Ingredients 2
... A large-scale data review by researchers in China of ... the endoscopic procedure to be safe and effective for ... a pooled detection rate of 68.1 percent for all ... be the most common indication, with a relatively high ...
... cancer patients who use a new combination of the ... Gy) before surgery have an 88 percent chance of ... randomized trial presented at the plenary session, October 3, ... Society for Radiation Oncology (ASTRO). "The results of ...
... 2011) Researchers in Japan have completed a study showing ... pulp can be grafted and produce bone regeneration between parents ... of Cell Transplantation (20:7), now freely ... a number of reasons, and autogenous bone grafting - using ...
... , MONDAY, Sept. 26 (HealthDay News) -- ... inhibitor (SSRI) antidepressants and antiplatelet drugs such as aspirin ... those who take anti-clotting drugs only, a new study ... and Lexapro. Antiplatelet drugs prevent blood cells from ...
... the Witwatersrand goldfields, not far from bustling Johannesburg, South Africa, ... littered with mounds of waste and underlain by a deep ... with water. Today, the mines are producing less and less ... estimate the volume of acid mine drainage from abandoned mines ...
... Eating fruits and vegetables may reduce the risk of some ... examined the diets of 918 colorectal cancer patients and 1,021 ... consumption of certain vegetables and fruits were associated with a ... -- that is, the upper and lower portions of the ...
Cached Medicine News:Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 2Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 3Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 4Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:Cell Transplantation study shows bone growth from implanted tooth and dental pulp stem cells 2Health News:Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients 2Health News:Broccoli, Cabbage, Other Veggies May Protect Against Colon Cancer 2
Touch-Trol Suction Catheter Mini-Tray...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Suction Catheter Kits with Sterile Saline (Bottle)...
Our suction kits include a Tri-Flo® suction catheter, a pop-up solution basin and two sturdy, precuffed latex exam gloves in an inner wallet. Infant and pediatric kits (5/6, 8 and 10 Fr) feature ...
Medicine Products: